Gene prioritization within mapped disease-risk loci from genome-wide association studies (GWAS) remains one of the central bioinformatic challenges of human genetics. This problem is abundantly clear in Alzheimer’s Disease (AD) which has several dozen risk loci, but no therapeutically effective drug target. Dominant strategies emphasize alignment between molecular quantitative trait loci (mQTLs) and disease risk loci, under the assumption that cis-regulatory drivers of gene expression or protein abundance mediate disease risk. However, mQTL data do not capture clinically relevant time points or they derive from bulk tissue. These limitations are particularly significant in complex diseases like AD where access to diseased tissue occurs only in end-stage disease, while genetically encoded risk events accumulate over a lifetime. Network-based functional predictions, where bioinformatic databases of gene interaction networks are used to learn disease-associated gene networks to prioritize genes, complement mQTL-based prioritization. The choice of input network, however, can have a profound impact on the output gene rankings, and the optimal tissue network may not be known a priori. Here, we develop a natural extension of the popular NetWAS approach to gene prioritization that allows us to combine information from multiple networks at once. We applied our multi-network (MNFP) approach to AD GWAS data to prioritize candidate genes and compared the results to baseline, single-network models. Finally, we applied the models to prioritize genes in recently mapped AD risk loci and compared our prioritizations to the state-of-the-art mQTL approach used to functionally prioritize genes within those loci. We observed a significant concordance between the top candidates prioritized by our MNFP method and those prioritized by the mQTL approach. Our results show that network-based functional predictions are a strong complement to mQTL-based approaches and are significant to the AD genetics community as they provide a strong functional rationale to mechanistically follow-up novel AD-risk candidates.